Yap TA - Search Results

1

Cabazitaxel in metastatic castration-resistant prostate cancer.

Yap TA, Pezaro CJ, de Bono JS. Yap TA, et al. Expert Rev Anticancer Ther. 2012 Sep;12(9):1129-36. doi: 10.1586/era.12.88. Expert Rev Anticancer Ther. 2012. PMID: 23098113 Review.

2

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18619560 Review.

3

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: yap ta. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.

4

Envisioning the future of early anticancer drug development.

Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.

5

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.

Yap TA, Olmos D, Molife LR, de Bono JS. Yap TA, et al. Expert Opin Investig Drugs. 2011 Sep;20(9):1293-304. doi: 10.1517/13543784.2011.602630. Epub 2011 Jul 22. Expert Opin Investig Drugs. 2011. PMID: 21777167 Review.

6

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Sandhu SK, Yap TA, de Bono JS. Sandhu SK, et al. Among authors: yap ta. Curr Drug Targets. 2011 Dec;12(14):2034-44. doi: 10.2174/138945011798829438. Curr Drug Targets. 2011. PMID: 21777194 Review.

7

The changing therapeutic landscape of castration-resistant prostate cancer.

Yap TA, Zivi A, Omlin A, de Bono JS. Yap TA, et al. Nat Rev Clin Oncol. 2011 Aug 9;8(10):597-610. doi: 10.1038/nrclinonc.2011.117. Nat Rev Clin Oncol. 2011. PMID: 21826082 Review.

8

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Yap TA, et al. Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Nat Rev Drug Discov. 2016. PMID: 27444228 Review.

9

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA. O'Carrigan B, et al. Among authors: yap ta. Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318518 Free PMC article.

10

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.

Collins DC, Sundar R, Constantinidou A, Dolling D, Yap TA, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Collins DC, et al. Among authors: yap ta. BMC Cancer. 2020 Dec 9;20(1):1210. doi: 10.1186/s12885-020-07662-y. BMC Cancer. 2020. PMID: 33298007 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters